Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain

Journal of Neuroscience

Volumn 25, Issue 12, 2005, Pages 3126-3131

  Ghilardi, Joseph R ^a,b   Röhrich, Heidi ^a   Lindsay, Theodore H ^a   Sevcik, Molly A ^a   Schwei, Matthew J ^a   Kubota, Kazufumi ^a   Halvorson, Kyle G ^a   Poblete, Jeannie ^c   Chaplan, Sandra R ^d   Dubin, Adrienne E ^d   Carruthers, Nicholas I ^d   Swanson, Devin ^d   Kuskowski, Michael ^b   Flores, Christopher M ^e   Julius, David ^c   Mantyh, Patrick W ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^e J W Johnson Pharmaceutical Res I   (United States)

Author keywords

Metastasis; Nociception; Skeletal malignancies; Therapy; Tumor; Vanilloid receptor

Indexed keywords

ANALGESIC AGENT; CATION CHANNEL; JNJ 17203212; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRPV1 ANTAGONIST; UNCLASSIFIED DRUG; VANILLOID RECEPTOR; VANILLOID RECEPTOR 1;

ACIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE CANCER; BONE METASTASIS; CANCER PAIN; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENE; GENE DISRUPTION; MALE; MOUSE; NOCICEPTIVE RECEPTOR; NONHUMAN; OSTEOCLAST; PRIORITY JOURNAL; RECEPTOR BLOCKING; SENSORY NERVE CELL; TRPV1 GENE;

ACTIVATING TRANSCRIPTION FACTOR 3; ANALGESICS; ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BONE AND BONES; BONE NEOPLASMS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FUNCTIONAL LATERALITY; GANGLIA, SPINAL; GENE EXPRESSION REGULATION, NEOPLASTIC; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NERVE FIBERS; PAIN; PAIN MEASUREMENT; TRPV CATION CHANNELS;

EID: 20144388484     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3815-04.2005     Document Type: Article

References (40)

1. Adami S (1997) Bisphosphonates in prostate carcinoma. Cancer 80:1674-1679.
2. Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, Dreicer R, Kuross SA, Lipton A, Seaman JJ (2001) Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91:1191-1200.
3. Bevan S, Geppetti P (1994) Protons: small stimulants of capsaicin-sensitive sensory nerves. Trends Neurosci 17:509-512.
4. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997) The capsaidn receptor: a heat-activated ion channel in the pain pathway. Nature 389:816-824.
5. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, Koltzenburg M, Basbaum AI, Julius D (2000) Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288:306-313.
6. Clohisy DR, Ramnaraine ML (1998) Osteoclasts are required for bone tumors to grow and destroy bone. J Orthop Res 16:660-666.
7. Coleman RE (1997) Skeletal complications of malignancy. Cancer 80:1588-1594.
8. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165-176.
9. Coyle N, Adelhardt J, Foley KM, Portenoy RK (1990) Character of terminal illness in the advanced cancer patient: pain and other symptoms during the last four weeks of life. J Pain Symptom Manage 5:83-93.
10. Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, Harries MH, Latcham J, Clapham C, Atkinson K, Hughes SA, Rance K, Grau E, Harper AJ, Pugh PL, Rogers DC, Bingham S, Randall A, Sheardown SA (2000) Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405:183-187.
11. Dax S, Dubin A, Jetter M, Nasser N, Shah C, Swanson D, Carruthers NI (2002) Vanilloid receptor antagonists: structure activity relationships via parallel and targeted synthesis. Int Symp Med Chem 27:93.
12. Delaisse J-M, Vaes G (1992) Mechanism of mineral solubilization and matrix degradation in osteoclastic bone resorption. In: Biology and physiology of the osteoclast (Rifkin BR, Gay CV, eds), pp 289-314. Ann Arbor, MI: CRC.
13. de Wit R, van Dam F, Loonstra S, Zandbelt L, van Buuren A, van der Heijden K, Leenhouts G, Huijer Abu-Saad H (2001) The Amsterdam Pain Management Index compared to eight frequently used outcome measures to evaluate the adequacy of pain treatment in cancer patients with chronic pain. Pain 91:339-349.
14. Drube S, Liebmann C (2000) In various tumour cell lines the peptide bradykinin B(2) receptor antagonist, Hoe 140 (icatibant), may act as mitogenic agonist. Br J Pharmacol 131:1553-1560.
15. Griffiths JR (1991) Are cancer cells acidic? Br J Cancer 64:425-427.
16. Honore P, Menning PM, Rogers SD, Nichols ML, Mantyh PW (2000a) Neurochemical plasticity in persistent inflammatory pain. Prog Brain Res 129:357-363.
17. Honore P, Luger N, Sabino M, Schwei M, Rogers S, Mach D, O'Keefe P, Ramnaraine M, Clohisy D, Mantyh P (2000b) Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6:521-528.
18. Hunt SP, Pini A, Evan G (1987) Induction of c-fos-like protein in spinal cord neurons after sensory stimulation. Nature 328:632-634.
19. Ji RR, Samad TA, Jin SX, Schmoll R, Woolf CJ (2002) p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 36:57-68.
20. Julius D, Basbaum AI (2001) Molecular mechanisms of nociception. Nature 413:203-210.
21. Luger NM, Honore P, Sabino MAC, Schwei MJ, Rogers SD, Mach DB, Clohisy DR, Mantyh PW (2001) Osteoprotegerin diminishes advanced bone cancer pain. Cancer Res 61:4038-4047.
22. Krishtal OA, Pidoplichko VI (1980) A receptor for protons in the nerve cell membrane. Neuroscience 5:2325-2327.
23. Mach DB, Rogers SD, Sabino MAC, Luger NM, Schwei MJ, Pomonis JD, Keyser CP, Clohisy DR, Adams DJ, O'Leary P, Mantyh PW (2002) Origins of skeletal pain: sensory and sympathetic innervation of the mouse femur. Neuroscience 113:155-166.
24. Major PP, Lipton A, Berenson J, Hortobagyi G (2000) Oral bisphosphonates: a review of clinical use in patients with bone metastases. Cancer 88:6-14.
25. Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP (2002) Molecular mechanisms of cancer pain. Nat Rev Cancer 2:201-209.
26. Marchetti D, Denkins Y, Reiland J, Greiter-Wilke A, Galjour J, Murry B, Blust J, Roy M (2003) Brain-metastatic melanoma: a neurotrophic perspective. Pathol Oncol Res 9:147-158.
27. Mercadante S, Arcuri E (1998) Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 24:425-432.
28. Michael GJ, Priestley JV (1999) Differential expression of the mRNA for the vanilloid receptor subtype 1 in cells of the adult rat dorsal root and nodose ganglia and its downregulation by axotomy. J Neurosci 19:1844-1854.
29. Mujoomdar M, Hoskin D, Blay D (2003) Adenosine stimulation of the proliferation of colorectal carcinoma cell lines. Biochem Pharmacol 66:1737-1747.
30. Portenoy RK, Payne D, Jacobsen P (1999) Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81:129-134.
31. Priestley JV, Michael GJ, Averill S, Liu M, Willmott N (2002) Regulation of nociceptive neurons by nerve growth factor and glial cell line derived neurotrophic factor. Can J Physiol Pharmacol 80:495-505.
32. Reeh PW, Steen KH (1996) Tissue acidosis in nociception and pain. Prog Brain Res 113:143-151.
33. Sabino MAC, Ghilardi JR, Jongen JL, Keyser CP, Luger NM, Mach DB, Peters CM, Rogers SD, Schwei MJ, de Felipe C, Mantyh PW (2002) Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 62:7343-7349.
34. Schwei MJ, Honore P, Rogers SD, Salak-Johnson JL, Finke MP, Ramnaraine ML, Clohisy DR, Mantyh PW (1999) Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain. J Neurosci 19:10886-10897.
35. Sevcik MA, Luger NM, Mach DB, Sabino MAC, Peters CM, Ghilardi JR, Schwei MJ, Rohrich H, De Felipe C, Kuskowski MA, Mantyh PW (2004) Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. Pain 111:169-180.
36. Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, Julius D (1998) The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 21:531-543.
37. Tsujino H, Kondo E, Fukuoka T, Dai Y, Tokunaga A, Miki K, Yonenobu K, Ochi T, Noguchi K (2000) Activating transcription factor 3 (ATF3) induction by axotomy in sensory and motoneurons: a novel neuronal marker of nerve injury. Mol Cell Neurosci 15:170-182.
38. Tsuzuki K, Kondo E, Fukuoka T, Yi D, Tsujino H, Sakagami M, Noguchi K (2001) Differential regulation of P2X(3) mRNA expression by peripheral nerve injury in intact and injured neurons in the rat sensory ganglia. Pain 91:351-360.
39. Woolf CJ, Salter MW (2000) Neuronal plasticity: increasing the gain in pain. Science 288:1765-1769.
40. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T (2000) Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88:2979-2988.